A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

NCT07222761 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

915

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed and/or Refractory Multiple Myeloma (RRMM)

Interventions

DRUG: Linvoseltamab
DRUG: Carfilzomib
DRUG: Daratumumab
DRUG: Dexamethasone
DRUG: Pomalidomide
DRUG: Bortezomib

Sponsor

Regeneron Pharmaceuticals